Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-12 18:40 • The Motley Fool Positive Axe Cap view: Selective

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

Axe note: Abbott’s steady valuation and cash flow make it a better bet than Intuitive Surgical’s premium growth story.

2026-10-12 18:30 • The Motley Fool Neutral Axe Cap view: Selective

The S&P 500 and Nasdaq have reached all-time highs, but the CAPE ratio has surpassed 40 for only the second time since 1871, echoing the dot-com bubble of 1999. While this valuation metric historically signals overvaluation and precedes bear markets, history shows that long-term investors who stay invested in quality companies recover and thrive despite short-term volatility.

Axe note: With the CAPE ratio mirroring the 1999 dot-com bubble, risks loom, yet sticking to quality stocks pays off in the long run.

2026-10-12 18:25 • The Motley Fool Negative Axe Cap view: Bearish

Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.

Axe note: Rising costs and declining core revenue suggest caution on Tilray despite headline revenue growth.